PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2008 | 3 | 3 | 327-331
Article title

Detection and identification of atypical quetiapine metabolite in urine

Content
Title variants
Languages of publication
EN
Abstracts
EN
Quetiapine fumarate (Seroquel®) is an atypical antipsychotic dibenzothiazepine derivative. Due to its extensive hepatic metabolism and low level of unchanged excretion (< 1%) the routine toxicological drug-screening analyses of urine often leads to false negative results. In the present study, we report that a newly identified metabolite of quetiapine, N-desalkylquetiapine, can be used as an indicative marker of quetiapine-intake in urine using common GC-MS screening procedure. The structure of the mentioned metabolite was solved from the mass-spectrum obtained and the quetiapine presence was proved by consequent HPLC plasma analysis.
Publisher

Journal
Year
Volume
3
Issue
3
Pages
327-331
Physical description
Dates
published
1 - 9 - 2008
online
10 - 7 - 2008
Contributors
author
  • Clinic of Emergency Toxicology and Allergology, Military Medical Academy, 3 G. Sofiiski Str, 1603, Sofia, Bulgaria
  • Laboratory of Bioinorganic and Bioanalytical Chemistry, Department of Analytical Chemistry, Faculty of Chemistry, Sofia University, 1 J. Bourchier Ave., 1164, Sofia, Bulgaria, MMitewa@chem.uni-sofia.bg
References
  • [1] Goldstein J., Arvanitis L. A., ICI 204,636 (Seroquel): A dibenzothiazepine atypical antipsychotic, Review of preclinical pharmacology and highlights of Phase II clinical trials, CNS Drug Rev., 1995, 1, 50–73 http://dx.doi.org/10.1111/j.1527-3458.1995.tb00276.x[Crossref]
  • [2] Arvanitis L. A., Miller B. G., Multiple fixed doses of ’seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 study Group, Biol. Psychiatry, 1997, 2, 233–46 http://dx.doi.org/10.1016/S0006-3223(97)00190-X
  • [3] Caccia S., New antipsychotic agents for schizophrenia: Pharmacokinetics and metabolism update, Curr. Opin. Invest. Drugs, 2002, 3, 1073–1080
  • [4] De Vane C. L., Nemeroff C. B., Clinical Pharmacokinetics of Quetiapine: An Atypical Antipsychotic, Clin. Pharmacokinet., 2001, 40, 509–522 http://dx.doi.org/10.2165/00003088-200140070-00003[Crossref]
  • [5] Hasselstrom J., Linnet K., In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions, Drug Metabol. Drug Interact., 2006, 21, 187–211 [PubMed]
  • [6] Flammia D. D., Valouch T., Venuti S., Tissue distribution of quetiapine in 20 cases in Virginia, J. Anal. Toxicol., 2006, 30, 287–292 [Crossref]
  • [7] Hopenwasser J., Mozayani A., Danielson T. J., Harbin J., Narula H. S., Posey D. H., et al., Postmortem Distribution of the Novel Antipsychotic Drug Quetiapine, J. Anal. Toxicol., 2004, 28, 264–268 [Crossref]
  • [8] Langman L. J., Kaliciak H. A., Carlyle S., Fatal overdoses associated with quetiapine, J. Anal. Toxicol., 2004, 28, 520–525 [Crossref]
  • [9] Saracino M. A., Mercolini L., Flotta G., Albers L. J., Merli R., Raggi M. A., Simultaneous determination of fluvoxamine isomers and quetiapine in human plasma by means of high-performance liquid chromatography, J. Chromatogr. B, 2006, 843, 227–233 http://dx.doi.org/10.1016/j.jchromb.2006.06.001[Crossref]
  • [10] Mandrioli R., Fanali S., Ferranti A., Raggi M. A., HPLC analysis of the novel antipsychotic drug quetiapine in human plasma, J. Pharm. Biomed. Anal., 2002, 30, 969–977 http://dx.doi.org/10.1016/S0731-7085(02)00395-3[Crossref]
  • [11] Anderson D.T., Fritz K.L..Quetiapine (Seroquel®) concentrations in seven postmortem cases, J. Anal. Toxicol., 2000, 24, 300–304 [Crossref]
  • [12] Davis P. C., Wong J., Gefvert O., Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection, J. Pharm. Biomed. Anal., 1999, 20, 271–282 http://dx.doi.org/10.1016/S0731-7085(99)00036-9[Crossref]
  • [13] Schulz M., Schmoldt A., Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics, Pharmazie, 2003, 58, 437–474
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-008-0015-0
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.